DCM
DAFNA Capital Management Portfolio holdings
AUM
$362M
This Quarter Return
-19.23%
1 Year Return
-0.48%
3 Year Return
+117.01%
5 Year Return
+181.93%
10 Year Return
+1,483.26%
AUM
$384M
AUM Growth
+$384M
(-3.5%)
Cap. Flow
+$76M
Cap. Flow
% of AUM
19.81%
Top 10 Holdings %
Top 10 Hldgs %
46.53%
Holding
98
New
11
Increased
36
Reduced
12
Closed
4
Top Buys
| 1 |
SPDR S&P Biotech ETF
XBI
|
$24.2M |
| 2 |
iShares Biotechnology ETF
IBB
|
$8.03M |
| 3 |
Fate Therapeutics
FATE
|
$4.99M |
| 4 |
Apellis Pharmaceuticals
APLS
|
$4.77M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$3.51M |
Top Sells
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$11.1M |
| 2 |
OTIC
Otonomy, Inc.
OTIC
|
$1.69M |
| 3 |
HOOK
HOOKIPA Pharma
HOOK
|
$747K |
| 4 |
Xenon Pharmaceuticals
XENE
|
$688K |
| 5 |
ProQR Therapeutics
PRQR
|
$685K |
Sector Composition
| 1 | Healthcare | 86.03% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stereotaxis
STXS
$261M
| $51M | 13.3% | 13,680,554 | – | – |
|
|
2
SPDR S&P Biotech ETF
XBI
$5.07B
| $24.2M | 6.31% | +269,500 | New | +$24.2M |
|
|
3
Fate Therapeutics
FATE
$120M
| $19.4M | 5.06% | 500,930 +128,770 | +35% | +$4.99M |
|
|
BPMC
4
DELISTED
Blueprint Medicines
BPMC
| $15.7M | 4.1% | 246,280 +39,369 | +19% | +$2.51M |
|
5
Adicet Bio
ACET
$59.9M
| $14.3M | 3.73% | 715,872 -17,300 | -2% | -$345K |
|
|
6
iShares Biotechnology ETF
IBB
$5.6B
| $13.4M | 3.48% | 102,500 +61,600 | +151% | +$8.03M |
|
|
7
Xenon Pharmaceuticals
XENE
$2.98B
| $11.6M | 3.03% | 380,163 -22,504 | -6% | -$688K |
|
|
KRTX
8
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $10.4M | 2.71% | 82,053 +9,630 | +13% | +$1.22M |
|
9
DexCom
DXCM
$29.5B
| $9.28M | 2.42% | 18,138 | – | – |
|
|
BHVN
10
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $9.2M | 2.4% | 77,600 +19,500 | +34% | +$2.31M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $7.84M | 2.04% | 83,655 | – | – |
|
12
Cytokinetics
CYTK
$4.23B
| $7.79M | 2.03% | 211,495 +77,401 | +58% | +$2.85M |
|
13
Nurix Therapeutics
NRIX
$714M
| $7.61M | 1.98% | 543,344 +237,024 | +77% | +$3.32M |
|
|
MORF
14
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $7.29M | 1.9% | 181,467 | – | – |
|
|
CSII
15
DELISTED
Cardiovascular Systems, Inc.
CSII
| $6.49M | 1.69% | 286,988 | – | – |
|
16
Syndax Pharmaceuticals
SNDX
$1.41B
| $6.47M | 1.68% | 371,987 +75,452 | +25% | +$1.31M |
|
17
Merus
MRUS
$4.98B
| $6.21M | 1.62% | 234,989 +8,900 | +4% | +$235K |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $5.97M | 1.56% | 180,306 | – | – |
|
19
Revolution Medicines
RVMD
$7.1B
| $5.92M | 1.54% | 232,101 +19,870 | +9% | +$507K |
|
20
IDEAYA Biosciences
IDYA
$2.15B
| $5.48M | 1.43% | 490,061 +30,000 | +7% | +$336K |
|
|
CBAY
21
DELISTED
Cymabay Therapeutics
CBAY
| $5.26M | 1.37% | 1,692,569 -95,000 | -5% | -$295K |
|
|
ISEE
22
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $5.02M | 1.31% | 298,476 +22,500 | +8% | +$379K |
|
|
NTUS
23
DELISTED
Natus Medical Inc
NTUS
| $5.01M | 1.31% | 190,635 | – | – |
|
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $4.77M | 1.24% | +93,935 | New | +$4.77M |
|
25
AtriCure
ATRC
$1.84B
| $4.73M | 1.23% | 72,029 | – | – |
|